Table 13.6i
Immunosuppression Use for Antirejection Treatment from Transplant to One Year Following Transplantation, 1995 to 2004
Recipients with Heart-Lung Transplants

	Year of Transplant									
	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Transplants	69	39	62	47	51	48	27	33	29	39
Tx with Antirejection Treatments	35	9	13	25	18	16	4	8	8	11
Antibodies										
Any in Category	8.6%	11.1%	15.4%	20.0%	5.6%	18.8%	0.0%	0.0%	12.5%	18.2%
Atgam/NRATG/NRATS	5.7%	11.1%	7.7%	16.0%	0.0%	6.3%	0.0%	0.0%	12.5%	0.0%
OKT3	2.9%	0.0%	7.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Thymoglobulin	0.0%	0.0%	0.0%	4.0%	5.6%	0.0%	0.0%	0.0%	0.0%	18.2%
Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	12.5%	0.0%	0.0%	0.0%	0.0%
Corticosteroids										
Any in Category	100.0%	100.0%	100.0%	92.0%	94.4%	93.8%	100.0%	100.0%	62.5%	100.0%
Steroids	100.0%	100.0%	100.0%	92.0%	94.4%	93.8%	100.0%	100.0%	62.5%	100.0%
Antimetabolites										
Any in Category	5.7%	0.0%	0.0%	4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Methotrexate	5.7%	0.0%	0.0%	4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.